HARVONI (ledipasvir/sofosbuvir) is a direct acting antiviral used to treat hepatitis C. Previous studies have shown similar success rates when treating HCV with HARVONI in both co-infected and mono-infected populations. We conducted a proportional hazards regression to determine differences in time-to-treat between co-infected and mono-infected patients. The study population consisted of 222 HCV infected patients treated with HARVONI, including 197 HCV mono-infected and 25 HCV/HIV co-infected patients, at the Atlanta Veterans Affairs (VA) Medical Center (Georgia) from January 2015 through March 2016. The two groups had similar age, gender distributions, and HCV viral loads at baseline. Significantly higher numbers of Non-Hispanic Blacks were present in the HCV/HIV co-infected group (18.5% more, p-value = 0.03). A significantly greater proportion of the HCV/HIV co-infected group was found to be adherent to their medication (13.3% higher, p-value = 0.03), but this was not considered a confounder during the analysis. We determined hazard ratios for time to complete treatment and time to complete a normal course of treatment at 1.15 (95% Confidence Interval: 0.75 - 1.76) and 1.07 (95% CI: 0.68 - 1.68), respectively. These results suggest that the time-to-treat HCV for HCV/HIV co-infected patients is no different than for HCV mono-infected patients.
Table of Contents
TABLE OF CONTENTS
About this Master's Thesis
|Committee Chair / Thesis Advisor|
|Duration of Hepatitis C Treatment with Direct-acting Antivirals Ledipasvir/Sofosbuvir Not Associated with HIV Co-Infection ()||2018-08-28 16:28:25 -0400||